Research programme: phosphodiesterase IV inhibitors - Memory Pharmaceuticals

Drug Profile

Research programme: phosphodiesterase IV inhibitors - Memory Pharmaceuticals

Alternative Names: MEM-1018; MEM-1091; MEM-1917; PDE4 inhibitors - Memory; R 1627

Latest Information Update: 29 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Memory Pharmaceuticals
  • Developer Memory Pharmaceuticals; Roche
  • Class Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease; Major depressive disorder

Most Recent Events

  • 29 Mar 2010 Discontinued - Preclinical for Alzheimer's disease in USA (PO)
  • 20 Mar 2008 Discontinued - Preclinical for Depression in USA (PO)
  • 14 Mar 2008 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top